| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018432896 |
| P356 | DOI | 10.1038/SJ.ONC.1208518 |
| P698 | PubMed publication ID | 15750627 |
| P5875 | ResearchGate publication ID | 7982862 |
| P2093 | author name string | Gyorgy Petrovics | |
| Shiv Srivastava | |||
| Yongmei Chen | |||
| Chen Sun | |||
| Judd W Moul | |||
| Yidong Chen | |||
| Albert Dobi | |||
| Bungo Furusato | |||
| Isabell A Sesterhenn | |||
| Lakshmi Ravindranath | |||
| Martin Nau | |||
| Maryanne Vahey | |||
| Syed Shaheduzzaman | |||
| Vasantha Srikantan | |||
| Aijun Liu | |||
| David G McLeod | |||
| P2860 | cites work | The erg gene: a human gene related to the ets oncogene | Q24299030 |
| Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma | Q28248137 | ||
| Delineation of prognostic biomarkers in prostate cancer | Q29617971 | ||
| alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer | Q34121458 | ||
| Molecular biology of the Ets family of transcription factors | Q34174026 | ||
| Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients | Q34290030 | ||
| Oncogenes and tumor suppressor genes in prostate cancer | Q34393194 | ||
| Searching for the gatekeeper oncogene of prostate cancer | Q35173049 | ||
| Ets proteins in biological control and cancer | Q35701558 | ||
| Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes | Q37095280 | ||
| Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer | Q38348367 | ||
| Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. | Q40604496 | ||
| Prostate cancer | Q73703143 | ||
| ETS2 function is required to maintain the transformed state of human prostate cancer cells | Q77764261 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| transcriptome | Q252857 | ||
| overexpression | Q61643320 | ||
| P304 | page(s) | 3847-3852 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome | |
| P478 | volume | 24 |
| Q33772417 | 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion |
| Q34614232 | 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer |
| Q64253447 | A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges |
| Q36883091 | A causal role for ERG in neoplastic transformation of prostate epithelium. |
| Q36437601 | A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. |
| Q57790493 | Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome |
| Q33567270 | Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection |
| Q35125405 | Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods |
| Q36734752 | Androgen receptor and prostate cancer |
| Q33663401 | Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element |
| Q33270960 | Androgen responsive intronic non-coding RNAs |
| Q34009867 | Antibody-based detection of ERG rearrangement-positive prostate cancer |
| Q36280125 | Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum |
| Q38984564 | Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. |
| Q46530327 | Assays for prostate cancer : changing the screening paradigm? |
| Q53519887 | Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels. |
| Q33359279 | Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer |
| Q93271728 | Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer |
| Q37635618 | Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. |
| Q38404130 | Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network |
| Q37656233 | Biomarkers for prostate cancer detection |
| Q82194763 | Breaking the rules of cancer |
| Q30496149 | Cancer biomarker discovery: the entropic hallmark |
| Q38308020 | Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase |
| Q39909790 | Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer |
| Q42028012 | Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status. |
| Q37983732 | Clinical potential of the ERG oncoprotein in prostate cancer |
| Q37159136 | Clinical utility of prostate carcinoma molecular diagnostic tests. |
| Q91866538 | Comparative RNA-seq analysis reveals dys-regulation of major canonical pathways in ERG-inducible LNCaP cell progression model of prostate cancer |
| Q57693470 | Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer |
| Q58752317 | Correlating blood-based DNA methylation markers and prostate cancer risk in African-American men |
| Q41242418 | Correlation between ERG Fusion Protein and Androgen Receptor Expression by Immunohistochemistry in Prostate, Possible Role in Diagnosis and Therapy. |
| Q38336067 | Detecting and targetting oncogenic fusion proteins in the genomic era. |
| Q42028953 | Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. |
| Q57693488 | Die TMPRSS2-ETS-Genfusion beim Prostatakarzinom |
| Q36291246 | Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer |
| Q33714055 | Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect |
| Q26997884 | Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue |
| Q37656262 | Discovery of prostate cancer biomarkers by microarray gene expression profiling |
| Q58116001 | Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer |
| Q64981143 | ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men. |
| Q38681610 | ERG expression in prostate cancer: biological relevance and clinical implication |
| Q46522843 | ERG expression in prostate cancer: the prognostic paradox |
| Q84578015 | ERG gene rearrangement status in prostate cancer detected by immunohistochemistry |
| Q43247408 | ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer |
| Q39616982 | ERG oncogene modulates prostaglandin signaling in prostate cancer cells. |
| Q41489983 | ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification |
| Q41733293 | ERG oncoprotein expression in prostate carcinoma patients of different ethnicities |
| Q61446341 | ERG oncoprotein expression in prostatic acinar adenocarcinoma; clinicopathologic significance |
| Q35108911 | ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer |
| Q40054562 | ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma |
| Q39666134 | ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies |
| Q38165243 | ERG protein expression as a biomarker of prostate cancer. |
| Q41988183 | ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer |
| Q57693373 | ERG rearrangement is present in a subset of transition zone prostatic tumors |
| Q33682349 | ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development. |
| Q37573395 | ETS gene fusions in prostate cancer |
| Q37038888 | ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer |
| Q47152626 | Ectopic expression of TWIST1 upregulates the stemness marker OCT4 in the esophageal squamous cell carcinoma cell line KYSE30. |
| Q33803926 | Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells |
| Q83463350 | Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression |
| Q40028950 | Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer |
| Q37656229 | Emerging biological observations in prostate cancer |
| Q33798864 | Epithelial-mesenchymal transition in prostate cancer: an overview. |
| Q46504038 | Ethnicity and ERG frequency in prostate cancer |
| Q33822319 | Evaluation of ERG responsive proteome in prostate cancer |
| Q30494853 | Evaluation of the 8q24 prostate cancer risk locus and MYC expression. |
| Q43962349 | Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients. |
| Q40685677 | Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers |
| Q34170544 | Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. |
| Q36882701 | Fusion in the ETS gene family and prostate cancer |
| Q86636781 | Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia |
| Q34651198 | Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues |
| Q37139054 | Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. |
| Q37127440 | Genetic variation in the upstream region of ERG and prostate cancer |
| Q37085413 | Genetics and genomics of prostate cancer |
| Q91671998 | Genomic alterations of Tenascin C in highly aggressive prostate cancer: a meta-analysis |
| Q33312298 | Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy |
| Q38335697 | Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells |
| Q28269917 | Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression |
| Q81305110 | Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization |
| Q38318517 | Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer |
| Q102369213 | Identification of transcription factor co-regulators that drive prostate cancer progression |
| Q42350997 | Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas |
| Q91656496 | In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy |
| Q50672077 | Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos. |
| Q36435777 | Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models |
| Q43151067 | Interplay among Drosophila transcription factors Ets21c, Fos and Ftz-F1 drives JNK-mediated tumor malignancy |
| Q38399291 | Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer. |
| Q37110802 | Is it important to decipher the heterogeneity of "normal karyotype AML"? |
| Q35232584 | JunD-mediated repression of GADD45α and γ regulates escape from cell death in prostate cancer |
| Q33862890 | Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer |
| Q35961920 | Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1. |
| Q37501345 | Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. |
| Q37054053 | Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India |
| Q40038137 | Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer |
| Q84814749 | Marked heterogeneity of ERG expression in large primary prostate cancers |
| Q36759527 | Medical technologies for the diagnosis of prostate cancer |
| Q33784622 | Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer |
| Q38723072 | Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer |
| Q57112111 | Molecular Subtypes of Prostate Cancer |
| Q24629083 | Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets |
| Q33723651 | Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer |
| Q40118714 | Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR. |
| Q56915156 | Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial1Share senior authorship |
| Q80678643 | Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers |
| Q37446023 | New and novel markers for prostate cancer detection |
| Q38220183 | New concepts concerning prostate cancer screening. |
| Q41564129 | Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer |
| Q39090168 | Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer |
| Q35685920 | Oncogenic activation of ERG: A predominant mechanism in prostate cancer |
| Q33520853 | Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology |
| Q99205342 | Over-expression of BAALC and ERG is associated with poor outcome in acute myeloid leukemia |
| Q33685303 | Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence |
| Q28546607 | Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer |
| Q26752933 | PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer |
| Q38166577 | PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis |
| Q63187448 | Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: Preliminary results |
| Q38022057 | Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? |
| Q38405404 | Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers |
| Q55439000 | Precision medicine applications in prostate cancer. |
| Q50517488 | Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort. |
| Q34265721 | Predominance of ERG-negative high-grade prostate cancers in African American men. |
| Q92833746 | Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review |
| Q30244674 | Prognostic outlier genes for enhanced prostate cancer treatment |
| Q43117102 | Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma. |
| Q92410882 | Prostate Cancer Genomic Subtypes |
| Q52566012 | Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. |
| Q38185176 | Prostate cancer biomarkers: an update. |
| Q42699705 | Prostate cancer gene expression signature of patients with high body mass index |
| Q57133950 | Prostate cancer stem cells |
| Q33430210 | Prostate cancer-associated gene expression alterations determined from needle biopsies |
| Q34036065 | Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation |
| Q60367836 | Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies |
| Q51310744 | Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue. |
| Q33645816 | Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status. |
| Q42668422 | Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. |
| Q35631603 | Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors |
| Q37194503 | Recurrent gene fusions in prostate cancer |
| Q38102618 | Recurrent gene fusions in prostate cancer: their clinical implications and uses |
| Q33852664 | Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment |
| Q26851525 | Recurrent rearrangements in prostate cancer: causes and therapeutic potential |
| Q40044894 | Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer |
| Q33874370 | Regulation of androgen-responsive transcription by the chromatin remodeling factor CHD8. |
| Q51893327 | Reliability of a composite measure of social inclusion for people with psychiatric disabilities |
| Q37386939 | Risk factors for prostate cancer |
| Q38027974 | Role of splice variants in the metastatic progression of prostate cancer |
| Q57999041 | Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml |
| Q40067022 | Significance of the TMPRSS2:ERG gene fusion in prostate cancer. |
| Q38729033 | Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells |
| Q58701464 | Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer |
| Q31042968 | TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. |
| Q38482216 | TMPRSS2-ERG Gene Fusion and Clinicopathologic Characteristics of Korean Prostate Cancer Patients |
| Q39386421 | TMPRSS2-ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-analysis of Racial Differences |
| Q54529505 | TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. |
| Q36147719 | TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features |
| Q42145160 | TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy |
| Q37046014 | TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry. |
| Q36983532 | TMPRSS2-ETS fusion prostate cancer: biological and clinical implications |
| Q39577718 | TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. |
| Q54561352 | TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. |
| Q37285569 | Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition |
| Q55128284 | Targeting Splicing in Prostate Cancer. |
| Q37671778 | The challenge of risk stratification in acute myeloid leukemia with normal karyotype |
| Q37913983 | The changing therapeutic landscape of castration-resistant prostate cancer |
| Q38266909 | The evolution of prostate cancer therapy: targeting the androgen receptor |
| Q38444138 | The oncogene ERG: a key factor in prostate cancer |
| Q24676201 | Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement |
| Q38047103 | Toward the detection of prostate cancer in urine: a critical analysis. |
| Q28771711 | Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin |
| Q33296583 | Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens |
| Q42419243 | Translesion Synthesis Polymerases in the Prevention and Promotion of Carcinogenesis |
| Q38092578 | Urinary biomarkers for prostate cancer: a review |
| Q40986667 | Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer |
| Q37571461 | Urine markers in monitoring for prostate cancer. |
| Q37957896 | Using molecular markers to help predict who will fail after radical prostatectomy |
| Q84021943 | [Value of biomarkers in urology] |
| Q35207623 | miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. |
Search more.